Lv0
0 积分 2024-10-07 加入
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
1个月前
已完结
Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma
2个月前
已完结
Real World Analysis of the efficacy, prognosis, and safety of daratumumab, carfilzomib, and dexamethasone (DKd) in relapsed or refractory multiple myeloma patients
3个月前
已完结
Real World Analysis of the Efficacy, Prognosis and Safety of Daratumumab, Carfilzomib, and Dexamethasone (DKD) in Relapsed or Refractory Multiple Myeloma Patients
3个月前
已关闭
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma
3个月前
已完结
Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma
6个月前
已完结
Cardiac Amyloidosis
6个月前
已完结
A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients
6个月前
已完结
The Impact of Dynamic Assessment of Risk Stratification at the Time of Disease Progression in Patients with Multiple Myeloma
6个月前
已完结
The Impact of Dynamic Assessment of Risk Stratification at the Time of Disease Progression in Patients with Multiple Myeloma
6个月前
已关闭
皖公网安备34019202002308
